Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tadekinig Alpha
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Nippon Shinyaku
Deal Size : $686.0 million
Deal Type : Licensing Agreement
AB2 Bio Signs U.S. Option and Licensing Agreement with Nippon Shinyaku for Tadekinig Alfa
Details : Under the licensing agreement, Nippon received an option to acquire exclusive U.S. rights to commercialize r-hIL-18BP (tadekinig alfa) to treat NLRC4-MAS.
Product Name : r-hIL-18BP
Product Type : Protein
Upfront Cash : $6.0 million
January 27, 2025
Lead Product(s) : Tadekinig Alpha
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Nippon Shinyaku
Deal Size : $686.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Tadekinig Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : r-hIL-18BP (tadekinig alfa) is a recombinant human interleukin-18 binding protein inhibiting IL18. It captures excess free IL-18 mimicking the normal physiological situation, and therefore represents a well differentiated approach for the treatment of IL...
Product Name : r-hIL-18BP
Product Type : Protein
Upfront Cash : Inapplicable
July 03, 2023
Lead Product(s) : Tadekinig Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
